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Background. The effect of life-long treatment with the ACE
inhibitor ramipril on hypertension-induced histological changes in
the kidney was tested in stroke-prone spontaneously hypertensive
rats (SHR-SP).
Methods. One-month-old pre-hypertensive SHR-SP were ran-
domized into three groups of 45 animals each, and exposed via
drinking water for their lifetime to a dose of: 1 mg z kg21 z d21
ramipril (antihypertensive dose, HRA); 10 mg z kg21 z d21 slight
dose of ramipril (non-antihypertensive dose, LRA); or placebo.
Histological and biochemical assessments were conducted after 15
months in ten rats each, when about 80% of the placebo group
had died.
Results. Kidneys from placebo treated SHR-SP showed pro-
nounced arterial wall hypertrophy and sclerosis, arterial fibrinoid
necrosis, glomerulopathy and tubular interstitial injury that were,
in concert with normalized blood pressure, completely prevented
by HRA treatment. LRA treatment did not affect any blood
pressure increase, and also attenuated the development of arterial
wall hypertrophy, sclerosis and arterial fibrinoid necrosis, though
to a minor extent only, but did not change glomerular and
tubulointerstitial degeneration. These effects of ramipril were
associated with a dose-dependent inhibition of plasma and renal
tissue ACE activities as well as lower serum concentrations of
creatinine, but there were no changes in serum potassium.
Conclusions. Life-long HRA-induced ACE inhibition protects
against hypertension-induced renal damages in SHR-SP. This is
associated with a doubeling of the lifespan in these animals [1].
The incidence of hypertension-related disease states
such as chronic renal failure is increased in high risk
patients with long-lasting hypertension [2]. In a three year
follow-up study in patients with hypertension and chronic
non-diabetic nephropathy and proteinuria (Ramipril Effi-
cacy In Nephropathy - REIN Study) deterioration of renal
function under angiotensin converting enzyme (ACE) in-
hibition with ramipril almost ceased, and hence, kidney
survival increased as compared to blood pressure con-
trolled patients without ramipril [3]. Analogous to human
hypertensives, spontaneously hypertensive rats (SHR) de-
velop kidney damage that resembles nephropathy seen in
patients [4]. In such rats the onset of kidney damage was
delayed when treated for 12 weeks or 1.5 years with an
antihypertensive dose of perindopril or enalapril, respec-
tively, starting at the age of 15 weeks [4, 5]. Also, his-
topathological changes start to reverse in the kidneys of
73-week-old SHR after three weeks of treatment with an
antihypertensive dose of an ACE inhibitor [6].
It was recently shown that early onset life-long treatment
with ramipril in an antihypertensive dose doubled the
lifespan, and a non-antihypertensive dose prolonged the
lifespan from 15 to 18 months of stroke-prone spontane-
ously hypertensive rats (SHR-SP). This observation corre-
lated with preservation of cardiac function, metabolism and
size as well as endothelial function [1]. The present report
investigates the nephroprotection associated with this treat-
ment in animals developing malignant hypertension.
METHODS
Animals
Male SHR-SP were purchased from Møllegrad Denmark
at the age of one month. They were housed three per cage
under standardized conditions of temperature, humidity
and light. The rats had free access to standard diet (Al-
tromin® Maintenance Diet 1320, sodium content 0.2%)
and drinking water ad libitum. All experiments were per-
formed in accordance with the German animal protection
law.
Study design
As recently outlined, 135 animals were randomized into
three groups [1]. Each group (N 5 45) was treated via
drinking water with a high antihypertensive dose of ramipril
(HRA; 1 mg z kg21 z d21) [7], a low non-antihypertensive
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dose of ramipril (LRA; 10 mg z kg21 z d21) [7] known to
completely inhibit renal tissue ACE activity [8], or placebo.
Treatment commenced immediately after randomization
and was adjusted to the actual consumption of drinking
water. Histological and biochemical data as well as kidney
and adrenal gland weights of 10 animals per group were
assessed after 15 months, when about 80% of the placebo
group had died.
The rats were anesthetized with hexobarbitone, 80 mg/kg
i.p., for direct recording of mean arterial blood pressure in
the left carotid artery. Thereafter, blood samples, kidneys,
adrenals as well as other organs were removed for bio-
chemical and morphological analyses. ACE activities in
plasma and kidney were radioenzymatically measured using
3H-Gly-Gly as substrate (Hycor, ACE-activity test). Serum
potassium concentrations were measured by flame photom-
etry. Serum concentrations of creatinine were measured by
the creatinine PAP method, (Boehringer Mannheim).
Kidneys, adrenal glands, pancreas, mesenterium, testis
and epididymidis were fixed in 10% neutral buffered for-
malin and embedded in paraffin for light microscopic
examination. Two to 3 mm thick sections were stained with
hematoxylin and eosin, or with perjodic acid Schiff-orange
G according to PEARSE for detection of fibrin. Histolog-
ical examinations and associated scoring were performed in
a blinded and separate fashion by two investigators, and
eventually by consensus. Alterations of vessel walls, glo-
meruli, and interstitial sites were gradually classified for
hypertrophy, necrosis, and fibrosis from 0 5 no alteration
as observed in juvenile rats, to 5 5 massive destruction,
with 1 5 minimal, 2 5 low, 3 5 moderate, and 4 5 severe
as intermediate scores.
Statistical analysis
The data are given as mean 6 95% CI (confidence
interval limits; Table 1) or median with 95% CI (Table 2).
For exploratory purposes, one way ANOVA followed by
multiple pairwise comparisons according to Tukey were
employed on blood pressure and clinical chemistry data,
and MANOVA with Holm adjusted P values on organ
weights, while the Kruskal-Wallis tests of cumulative scores
were used for morphometric assessments, and rank ordered
Fig. 1. Overview of the kidney cortex (A) with arterial, glomerular and
tubulointerstitial injuries in placebo-treated SHR-SP, (B) minor
changes after LRA treatment (non-antihypertensive dose of ramipril, 10
mg z kg21 z d21), and (C) no changes after HRA treatment (antihyperten-
sive dose of ramipril, 1 mg z kg21 z d21). PEARSE staining, magnification
a - c 352.
Table 1. Plasma and kidney ACE activities, serum creatinine and
potassium concentrations in SHR-SP
Plasma






Placebo 166 6 17b,c 126 6 21b,c 63 6 11b 3.3 6 0.4
HRA 11 6 5a,c 10 6 2a,c 46 6 4a 3.4 6 0.2
LRA 68 6 13a,b 25 6 2a,b 53 6 4 3.5 6 0.3
Data are given as mean 6 95% CI. Abbreviations are: HRA: antihy-
pertensive high dose of ramipril (1 mg z kg21 z d21); LRA, non-antihyper-
tensive low dose of ramipril (10 mg z kg21 z d21).
a vs. Placebo, b vs. HRA, c vs. LRA, P , 0.05 by one way ANOVA
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analyses according to Spearman for correlations. Null-
hypotheses were rejected at P , 0.05.
RESULTS
Body weights increased from 72 68 g at the age of one
month to 366 6 17 g at the age of 15 months in placebo
treated SHR-SP. Ramipril treatments did not affect the
increases in body weights. As reported, systolic blood
pressure was 98 6 8 mm Hg in young (1 month old)
placebo treated SHR-SP as measured by tail plethysmog-
raphy, increased significantly over the following three
months, and climaxed after 12 months at 233 6 14 mm Hg.
Fig. 2. Arteriae intralobulares after placebo (A and B) and after LRA treatment (see Fig. 1) (C and D). (A) media hypertrophy and sclerosis and (B)
fibrinoid necrosis and periarteritis (like panarteritis nodosa); (C) minimal hypertrophy and no intimal sclerosis, and (D) fibrinoid necrosis, but not
combined with periarteritis. PEARSE staining, magnification A, C, D 3330, B 3130.
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At 15 months, mean arterial blood pressures measured in
the carotid artery were 150 6 mm Hg after placebo, 109 6
11 mm Hg after HRA and 156 6 12 mm Hg after LRA [1].
Kidney weights did not differ between the groups (right
kidneys, 471 6 16 g/100 g body wt; left kidneys, 476 6 19
mg/100 g body wt). Weights of adrenal glands were dose-
dependent less with either treatment independent of site:
placebo 107 6 14; HRA 76 6 6; LRA 91 6 10 mg/100 g
body wt).
Reductions in plasma and kidney ACE activities by
ramipril were dose-dependent (Table 1). Other compo-
nents of the renin-angiotensin system such as plasma renin
activities were increased only by HRA treatment, whereas
plasma angiotensin II (Ang II) and plasma aldosterone
were significantly reduced by both doses of ramipril [1].
Serum creatinine after HRA, was lower as compared to
placebo treated animals; however, serum potassium was
not changed by either dose of ramipril (Table 1).
Morphological evaluation of kidneys from placebo
treated SHR-SP showed arterial wall hypertrophy, intimal
sclerosis, arterial fibrinoid necrosis as well as glomerular
and tubulointerstitial injuries (Table 2, and Figs. 1A, 2 A,
B, and 3 A, B).
Middle to small sized arteries (A. arcuatae, interlobares
and afferentia) presented with marked hypertrophy of the
media combined with an enlargement of the intima (fibro-
elastosis) resulting in intense luminal stenosis (Fig. 2A),
while large interlobar arteries were not affected. These
alterations were accompanied by arterial fibrinoid wall
necrosis with inflammatory reactions in intima and adven-
titia (Fig. 2B). The extent of fibrinoid affections varied
from discrete intimal depositions to circumferential imbi-
bition with destruction or edemateous swelling of the
media containing erythrocytes or their debris as siderin
accumulating macrophages in the adventitia. However,
there were no signs of infarcteous loss of cortical paren-
chyma. In some cases the adventitia of these arteries, apart
from granulocytes, contained considerable amounts of
macrophages (Fig. 2B). Similar changes were found in
arteries of other organs such as the adrenal gland, pan-
creas, mesenterium, testis and epididymidis (Table 2).
Glomerular changes were found in two features: (1)
mostly juxtamedullary enlarged glomerula with ectatic cap-
illary loops, often with reduction of capillary and mesangial
cells and sometimes with fibrin thrombosis (Fig. 3A); and
(2) sclerotic changes ranging from segmental to total
capillary obliteration (Fig. 3B). Consequently, the Bow-
man’s capsular space contained often albumin or fibrin
(Figs. 1A, and 3 A, B).
There was a massive presence of protein casts in the
tubules (Fig. 1A), in the Henles loops and in the collecting
ducts as a consequence of an increased glomerular perme-
ability or destruction. Proximal tubules often contained an
accumulation of protein droplets. Tubular atrophies were
mainly localized close to sclerotic glomerula, and the
peritubular interstium showed round cell infiltration or
fibrosis corresponding to the degree of atrophy (Fig. 1A).
HRA treatment completely prevented arterial wall hy-
pertrophy and arterial necrotic lesions. On glomerular as
well as the tubulointerstitial changes HRA treatment was
less effective. However, these changes in HRA treated
SHR-SP appeared to be even less as compared to age
matched normotensive control rats (Langer, personal ob-
servation; Table 2, Figs. 1C and 4).
Treatment with LRA attenuated arterial wall hypertro-
phy in the kidneys (Table 4, Figs. 1B and 2 C, D) and
arterial necrotic lesions in testes (not further quantified),
but did not protect against glomerular and tubulointerstial
damages (Figs. 1B and 3 C, D). Moreover, the degree of
necrosis in kidneys of the LRA group was significantly less
in those affected as compared to placebo. The scatterplot
matrix revealed that the histological changes correlated to
blood pressure and plasma ACE activity, whereas kidney
ACE activity did not (Fig. 5). This correlation is based on
the changes under HRA, as attested by nonsignificant
Spearman rank correlation coefficients when the HRA data
are excluded (r 5 20.19 histomorphological score vs. blood
Table 2. Median scores of histological lesions in the kidneys observed in placebo and ramipril-treated SHR-SP at 15 months, and life expectancy
Placebo HRA LRA
C.I. (range) N affected C.I. (range) N affected C.I. (range) N affected
Hypertrophy of arterial wall 4.0 (3–4)b,c 10/10 0.0 (0–0)a,c 0/10 3.0 (2–3)a,b 10/10
Arterial fibrinoid necrosis 2.5 (0–4)b 6/10 0.0 (0–0)a,c 0/10 1.0 (0–1)b 7/10
Glomerulopathy 4.0 (3–4)b 10/10 1.0 (1–2)a,b 10/10 3.0 (3–4)b 10/10
Tubulointerstitial injuries 4.0 (3–4)b 10/10 1.0 (1–1)a,c 10/10 4.0 (3–4)b 10/10
Total scored 13.0 (9–16)b 2.0 (2–3)a,c 10.5 (9–13)b
Arterial fibrinoid necrosis in
other organs
3.0 (3–4) 10/10 0.0 (0–0) 0/10 1.0 (0–1) 10/10
Life expectancy days 423 (408–430)b,c 744 (535–767)a,c 456 (427–487)a,b
Data are given as median with 95% CI (range), and number of affected organs
a vs. Placebo, b vs. HRA, c vs. LRA, P , 0.05 by ANOVA on Ranks, d Median of individual sums
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pressure, 20.41 histomorphological score vs. ACE, 20.17
histomorphological score vs. kidney ACE).
DISCUSSION
Early onset life-long administration of the ACE inhibitor
ramipril to SHR-SP in an antihypertensive dose was able to
prevent hypertension-induced complications of the kidney
seen in placebo treated age-matched animals, while a dose
that did not affect the rise in blood pressure was only partly
effective. This nephroprotection, beyond the reported car-
dioprotective and vasculoprotective effects, is associated
with a dose-dependent lifespan extension [1].
Fig. 3. Glomeruli after placebo (A and B) and LRA treatment (see Fig. 1) (C and D). (A) fibrinoid necrosis in microcystic capillary loops, (B) sclerosis
with capillary obliteration; (C) enlarged glomerulum (like that in A) with widened capillary loops juxtamedullary typical for hypertension, (D) capillary
sclerosis with capsular adherence besides a normal glomerulum. PEARSE staining, magnification A - C 3330, D 3130.
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Fig. 4. After HRA treatment (see Fig. 1),
arteria arcuata (cross section below) and
intralobularis, glomerula and tubulointerstitial
area are without any change. PEARSE staining,
magnification 3130.
Fig. 5. Scatterplot correlation matrix with
normal curve density display of blood pressure
(BP), plasma angiotensin converting enzyme
(ACE), kidney ACE activity, and
histomorphological score (Score). Symbols are:
red (F) placebo; blue () HRA; and black (M)
LRA (see Fig. 1 for definitions).
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The beneficial effects of ACE inhibition with ramipril on
kidney morphology correlated with decreased plasma Ang
II and aldosterone concentrations, and lower weights of the
adrenal glands. They reflect the suppression of renin-
angiotensin system components in plasma and tissue, which
is most likely involved in the protection of the kidney. It has
been convincingly demonstrated in rats that chronic expo-
sure to Ang II causes an adverse increase in glomerular
capillary pressure that is associated with albuminuria and
glomerular sclerosis [9–11].
Also, locally increased kinins seem to be involved in the
prevention of renal injuries [12] by contributing to in-
creased renal blood flow and diuresis seen in animals with
low to normal renin levels under ACE inhibition [13].
Furthermore, impaired NO synthesis and release described
in rats [14] and also in aged hypertensive humans with
attentuated renal vascular dilation [15] may be prevented
by ACE inhibition [16].
The role of the recently described heptapeptide Ang 1-7,
formed by the neutral endopeptidase 24.11 from Ang I, is
subject of a scientific dispute, since it also acts through
specific receptors presumably involved in the control of
hydroelectrolyte balance [17–19].
The serum potassium concentrations did not differ be-
tween placebo and ramipril treated animals in this study,
which is not in line with the hypothesis that a reduced
propensity for arrhythmias due to a preserved potassium
concentration may have contributed to the lifespan exten-
sion in these SHR-SP. An increased sensitivity to epineph-
rine inducible arrhythmias was observed in potassium-
deficient rats [20], and moreover, less cardiac arrhythmias
in patients with congestive heart failure treated with ena-
lapril were associated with higher serum potassium concen-
trations [21].
The serum creatinine concentration was significantly
lower by long-term ACE inhibition as compared to the
placebo treatment. This is in context with results from a
double-blind controlled trial in patients with renal insuffi-
ciency caused by various disorders, where benazepril halved
the overall risk of progressive renal insufficiency, defined as
doubling of baseline serum creatinine as a surrogate pa-
rameter [22].
The histomorphological changes in the kidneys of place-
bo-treated SHR-SP (Figs. 1A, 2 A, B, and 3 A, B) were
mainly the result of chronic pressure overload. The fibrin-
oid necroses found in arteries and glomerula correspond to
the decompensating hypertension-induced nephrosclerosis
in humans. Therefore, the “early” death of placebo treated
animals was associated with strong renal injuries above
cardiac failure [1]. The considerable amount of macro-
phages and granulocytes (Fig. 2B) also found in some cases
in the adventitia of arteries in rats [23] corresponds to the
human panarteriitis nodosa.
No renal hypertensive degeneration was seen in HRA
treated animals. The marginal changes in glomerular and
tubulointerstitial areas can be viewed as the beginning of an
age-related nephropathy also seen in age-matched normo-
tensive control rats (Langer, personal observation).
The effect of ACE inhibition seems to be partly inde-
pendent of its antihypertensive action since LRA treatment
without effect on the development of high blood pressure
was also nephroprotective, although to a minor extent, as
only arterial hypertrophy, fibrinoid necrosis and sclerosis
were opposed (Figs. 1C and 2 C, D). This favors an
additional organoprotective effect in the kidney by inhibi-
tion of a locally activated renin-angiotensin system [24, 25],
and possibly by an improved endothelial function through
preserved NO availability [16]. However, the present study
clearly recommends that blood pressure must be controlled
to fully render ACE inhibition with both nephroprotective
and live saving doses of ramipril.
A similar study in spontaneously hypertensive rats with
enalapril in an antihypertensive dose did not demonstrate
the same degree of morphological protection [4]. Further-
more, the morphological changes in placebo treated ani-
mals were somewhat less dramatic [4]. The difference to
the present study may be due to the more severe hyperten-
sion developing in SHR-SP and the earlier commencement
of treatment with ramipril. Moreover, this ACE inhibitor is
endowed with higher affinity to the enzyme as compared to
enalapril, which consequently may result in the more
efficacious protection [26].
The present results show that the beneficial effects of
life-long antihypertensive ACE inhibitor treatment with
ramipril on renal morphology accompany and hence may
be causally linked to the doubeling of lifespan extension of
genetically hypertensive rats. Although these effects were
in part seen with the non-antihypertensive dose of ramipril,
the majority of the nephroprotectic effects was associated
with the prevention of the development of high blood
pressure. These data are in line with the advantageous
effects of ramipril in the REIN study in which the decline
in glomerular filtration rate and risk of terminal renal
failure in proteinuric, non-diabetic nephropathy were safely
reduced [3].
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